We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential enable/disable

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name	econda
Purpose	Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Statistics enable/disable

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name	econda
Purpose	Statistics

External media enable/disable

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name	YouTube
Purpose	Show YouTube content
Name	Twitter
Purpose	activate Twitter Feeds

Research

Research Group Cancer Drug Development

Dr. Aubry Miller / Dr. Nikolas Gunkel

The translation of new cancer research findings into novel therapeutics is of fundamental importance in the path toward A Life Without Cancer. The Cancer Drug Development Group takes the first step along this path: the discovery and development of small molecules with specific inhibitory profiles and phenotypic effects. These small molecule inhibitors can be used as research tools to help elucidate the role(s) that target proteins play in cancer, and can be starting points for more advanced drug development projects. Research projects in our group tackle topics such as target identification and validation, assay development for high throughput screening, chemical synthesis for inhibitor optimization and the development of chemical biology probes, and the establishment of cellular assays to profile our inhibitors. By collaborating with colleagues who are experts in basic, as well as, clinical research, we have established a unique academic drug discovery environment embedded in the scientific excellence of the DKFZ and NCT.

FUTURE OUTLOOK

We aim to work on innovative targets with clear clinical significance, and on new targets/pathways whose roles in cancer have yet to be fully unraveled.

We are part of the Helmholtz Drug Research Initiative.

Contact

Dr. Aubry Miller / Dr. Nikolas Gunkel

Cancer Drug Development (A390)

Deutsches Krebsforschungszentrum

Im Neuenheimer Feld 580

69120 Heidelberg

Dr. Aubry Miller
Tel: +49 6221 42 3307
Contact Form

Dr. Nikolas Gunkel
Tel: +49 6221 42 3419
Contact Form

Selected Publications

J. Samarin et al. “Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs” Redox Biol. 2023, 62, 102639.
R.R. Steimbach et al. "Aza-SAHA Derivatives are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 Knockout" J. Am. Chem. Soc., 2022, 144, 18861-18875.
S. Jänner et al. "Bioinspired Asymmetric Total Synthesis of Emeriones A–C" Angew. Chem. Int. Ed., 2022, 61, e202205878.
M. Morgen et al. "Inclusion Complexes of Gold(I)-Dithiocarbamates with ß-Cyclodextrin: A Journey from Drug Repurposing towards Drug Discovery" Chem. Eur. J. 2021, 27, 12156–12165.